Charles River Laboratories (CRL)
$177.62
$-4.06
(-2.23%)
As on 08-May-2026 16:00EDT
Market cap
$8,556 Mln
Revenue (TTM)
$4,027 Mln
P/E Ratio
--
P/B Ratio
2.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-170 Mln
-
ROE
-0.1 %
-
ROCE
-2.3 %
-
Industry P/E
--
-
EV/EBITDA
28
-
Debt to Equity
0
-
Book Value
$64.3
-
EPS
$-3.8
-
Face value
--
-
Shares outstanding
48,167,730
10 Years Aggregate
CFO
$4,684.98 Mln
EBITDA
$5,674.98 Mln
Net Profit
$2,748.66 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Charles River Laboratories (CRL)
| -11.0 | 4.8 | -3.3 | 29.7 | -2.4 | -12.3 | 8.2 |
|
BSE Sensex
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Midcap 400
| 10.5 | 7.9 | 3.1 | 27.0 | 14.6 | 6.0 | 9.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Charles River Laboratories (CRL)
| 8.1 | -21.8 | 8.5 | -42.2 | 50.8 | 63.6 | 35.0 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Charles River Laboratories (CRL)
|
177.6 | 8,555.6 | 4,027.0 | -184.7 | 11.3 | -5.9 | -- | 2.9 |
| 295.1 | 39,392.9 | 4,286.9 | 577.2 | 9.8 | 88.2 | 74.1 | 37.4 | |
| 48.4 | 7,571.7 | 1,210.8 | 109.6 | 13.1 | 5.4 | 69.1 | 3.6 | |
| 101.4 | 21,967.9 | 819.6 | -1,183.8 | -141.4 | -143.4 | -- | 40.0 | |
| 178.7 | 29,815.0 | 16,632.0 | 1,385.0 | 14.1 | 22.4 | 22.2 | 4.2 | |
| 54.4 | 21,565.3 | 2,225.0 | -3,194.0 | -143.4 | -38.2 | -- | 2.9 | |
| 714.9 | 74,948.4 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 17.5 | 2.4 | |
| 564.9 | 23,979.9 | 3,169.8 | 1,287.4 | 50.7 | 20.6 | 20.9 | 4.3 | |
| 53.0 | 7,654.0 | 0.0 | -946.5 | -- | -32.1 | -- | 3.1 | |
| 429.8 | 109,090.7 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 25.5 | 5.6 |
Shareholding Pattern
View DetailsAbout Charles River Laboratories (CRL)
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment... produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts. Read more
-
Chairman, CEO & President
Mr. James C. Foster J.D.
-
CEO, President & Chairman
Mr. James C. Foster J.D.
-
Headquarters
Wilmington, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Charles River Laboratories (CRL)
What is the current share price of Charles River Laboratories (CRL) Today?
The share price of Charles River Laboratories (CRL) is $177.62 (NYSE) as of 08-May-2026 16:00 EDT. Charles River Laboratories (CRL) has given a return of -2.43% in the last 3 years.
What is the current PB & PE ratio of Charles River Laboratories (CRL)?
Since, TTM earnings of Charles River Laboratories (CRL) is negative, P/E ratio is not available.
The P/B ratio of Charles River Laboratories (CRL) is 2.89 times as on 08-May-2026, a 35 discount to its peers’ median range of 4.42 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-68.02
|
3.10
|
|
2024
|
916.78
|
2.73
|
|
2023
|
25.71
|
3.39
|
|
2022
|
23.02
|
3.76
|
|
2021
|
49.68
|
7.66
|
What is the 52 Week High and Low of Charles River Laboratories (CRL)?
The 52-week high and low of Charles River Laboratories (CRL) are Rs 228.88 and Rs 132.58 as of 10-May-2026.
What is the market cap of Charles River Laboratories (CRL)?
Charles River Laboratories (CRL) has a market capitalisation of $ 8,556 Mln as on 08-May-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Charles River Laboratories (CRL)?
Before investing in Charles River Laboratories (CRL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.